In this interview, Peter Bains, CEO of Syngene, gives us a behind-the-scenes look at what makes his company stand out. He talks about their huge network of hospitals, which helps them access a lot of patients quickly – a big plus when it comes to running clinical trials and getting new drugs approved faster. Peter also shares how Syngene is working on a wide variety of therapies, from small molecules to large ones, and has big plans for the future. It’s a great conversation about how they’re really pushing the boundaries of drug development and clinical research.
TWENTYFOURSEVENBIOPHARMA